NIH supports genome editing and other biologic therapies for Alzheimer's disease-related dementias, from lead optimization and drug development through safety studies and early clinical evaluation.
Funding for Alzheimer's drug development from pre-clinical to Phase I clinical trials to prevent, slow, or treat AD symptoms, excluding basic research and non-pharmacological interventions.
Use mouse models to test existing and investigational drugs for Alzheimer's; focus on drug repositioning and combo therapy development.
This grant supports academic and biotech researchers in developing new drugs to prevent, slow, or treat Alzheimer’s disease through preclinical and early-stage clinical research.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
Accelerating Drug Discovery for Frontotemporal Degeneration supports researchers and clinicians developing small molecules and biologics to advance disease-modifying treatments for frontotemporal dementia.